Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

ASNC, SNMMI, PET standard, Pet cardiac imaging, PET nuclear imaging, perfusion imaging

An example of a cardiac PET-CT imaging, should a color coded image of the left ventricle to help assess myocardial perfusion to detect ischemia using a Siemens scanner.

News | Nuclear Imaging | July 19, 2016

July 19, 2016 - An updated joint American Society of Nuclear Cardiology (ASNC) imaging guidelines and Society of...

PET, mpMRI, prostate cancer detection, targeted biopsies, University of Michigan study, Morand Piert

The figure shows a Gleason 3+4 prostate cancer (arrows) as identified on T2-weighted (A) and diffusion-weighted (B) MRI, F-18-choline PET (C), as well as PET/MRI (D).

News | Prostate Cancer | July 14, 2016

July 14, 2016 — Adding F-18-choline positron...

Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium
News | Radiopharmaceuticals and Tracers | July 12, 2016

July 12, 2016 — Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the...

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers | July 07, 2016

July 7, 2016 — Cell>Point announced in mid-June it has entered into an...

personalized medicine
Feature | Radiology Imaging | July 06, 2016 | Greg Freiherr

Mammography may be the most recognizable — and singularly effective — type of personalized medicine, benefitting...

Feature | Molecular Imaging | July 06, 2016 | Melinda Taschetta-Millane

I recently attended the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San...

Navidea, Lymphoseek injection, breast cancer detction, scintigraphy, SNMMI 2016
News | Radiopharmaceuticals and Tracers | July 06, 2016

July 6, 2016 — Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the...

University of Southampton, Hodgkin lymphoma, chemotherapy response, bleomycin
News | PET Imaging | June 29, 2016

June 29, 2016 — Hodgkin lymphoma patients can be spared the serious side effects of chemotherapy thanks to high-tech...

SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE
News | Clinical Decision Support | June 27, 2016

June 27, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-...

News | Nuclear Imaging | June 24, 2016

June 24, 2016 — Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual...

PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016

June 23, 2016 — Cancer patients often experience significant fluctuations in weight and lean body mass (LBM)....

blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016

June 23, 2016 — Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and...

PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016

June 23, 2016 — The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many...

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016

June 23, 2016 — Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering...

VASH collimator, DOE, molecular breast imaging, SNMMI 2016

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half. Technologies developed at DOE’s Jefferson Lab for the variable angle slant hole collimator are included in two filings to the U.S. Patent and Trademark Office. Image courtesy of DOE’s Jefferson Lab.

News | Breast Imaging | June 21, 2016

June 21, 2016 — Preliminary tests have demonstrated that a new device may enable up to six times better contrast of...

pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016

June 20, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting...

SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
News | Prostate Cancer | June 17, 2016

June 17, 2016 — Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline...

Overlay Init